263 related articles for article (PubMed ID: 15368327)
1. Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
Ohba H; Zhelev Z; Bakalova R; Ewis A; Omori T; Ishikawa M; Shinohara Y; Baba Y
Cancer; 2004 Sep; 101(6):1390-403. PubMed ID: 15368327
[TBL] [Abstract][Full Text] [Related]
2. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
3. Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression.
Baker BE; Kestler DP; Ichiki AT
J Biomed Sci; 2006 Jul; 13(4):499-507. PubMed ID: 16547768
[TBL] [Abstract][Full Text] [Related]
4. Efficient silencing of bcr/abl oncogene by single- and double-stranded siRNAs targeted against b2a2 transcripts.
Rapozzi V; Xodo LE
Biochemistry; 2004 Dec; 43(51):16134-41. PubMed ID: 15610007
[TBL] [Abstract][Full Text] [Related]
5. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
6. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
Elmaagacli AH; Koldehoff M; Peceny R; Klein-Hitpass L; Ottinger H; Beelen DW; Opalka B
Haematologica; 2005 Mar; 90(3):326-34. PubMed ID: 15749664
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitory effect of RNA interference on chronic myeloid leukemia bcr/abl oncogene expression].
Ma XX; Wang C; Wei J; Qin YW; Yan SK; Gao YR; Cai Q
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):359-62. PubMed ID: 16185484
[TBL] [Abstract][Full Text] [Related]
8. Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Bakalova R; Ohba H; Zhelev Z; Kubo T; Fujii M; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Apr; 564(1-2):73-84. PubMed ID: 15094045
[TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
10. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
12. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
Wilda M; Fuchs U; Wössmann W; Borkhardt A
Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
[TBL] [Abstract][Full Text] [Related]
13. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ
Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
15. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
Withey JM; Harvey AJ; Crompton MR
Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
[TBL] [Abstract][Full Text] [Related]
16. RNA interference--about the reality to be exploited in cancer therapy.
Bakalova R
Methods Find Exp Clin Pharmacol; 2007; 29(6):417-21. PubMed ID: 17922071
[TBL] [Abstract][Full Text] [Related]
17. [Knockdown of cyclin A2 expression by small interfering RNA in MG-63 cells].
Liu Y; Ding JY; Shen WL; Zhao X; Fan SW
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):670-5. PubMed ID: 18246796
[TBL] [Abstract][Full Text] [Related]
18. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic effect of As2S2 on K562 cells and its mechanism.
Li JE; Wu WL; Wang ZY; Sun GL
Acta Pharmacol Sin; 2002 Nov; 23(11):991-6. PubMed ID: 12421474
[TBL] [Abstract][Full Text] [Related]
20. [Construction of eukaryotic expression vector of siRNA specific to bcr/abl fusion gene].
Xi YM; Liu T; Meng WT; Wang YH; Gu L; Lu XX; Gong YP
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):460-3. PubMed ID: 16078560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]